-
糖尿病是严重威胁人类健康的常见病和多发病。目前, 我国糖尿病患者将近4000万人, 位居世界第二位。糖尿病不仅给患者本人造成痛苦, 也给其家庭和社会带来沉重的负担。
糖尿病以高血糖为标志, 是由于胰岛β细胞选择性破坏或β细胞分泌胰岛素迟缓及胰岛素抵抗而使胰岛素分泌不足所致。β细胞的数量只有减少50%~60%时才会出现相关的症状。由于胰腺位置较深, β细胞含量少, 所以目前对β细胞量的检测是通过胰岛素分泌能力的测定来替代的, 但是血清胰岛素水平并不能精确反映β细胞量。因此, 如何通过无创性的方法早期进行β细胞量和功能的评估, 是目前分子影像学所面临的重要课题之一[1-2]。本文就胰岛β细胞疾病的分子核医学显像的进展进行综述。
胰岛β细胞的分子核医学显像进展
Progress in molecular nuclear medicine imaging of pancreatic beta cells
-
摘要: 糖尿病是严重威胁人类健康的常见病和多发病。糖尿病主要是由于胰岛β细胞选择性破坏或胰岛β细胞分泌胰岛素迟缓和胰岛素抵抗而使胰岛素相对不足所致。β细胞的数量只有减少50%~60%时才会出现相关的症状。由于胰腺位置较深,β细胞含量少,目前临床诊断主要采用有创性方法,且难于进行早期诊断。因此,通过无创性的方法进行β细胞相关代谢疾病的早期诊断,越来越受到人们的关注,影像学诊断也就成了关注焦点,但是如何进行β细胞数量和功能的评估仍是目前影像学诊断面临的重要课题。
-
关键词:
- 糖尿病 /
- 胰岛素分泌细胞 /
- 正电子发射断层显像术
Abstract: Diabetes mellitus is a common and frequently occurring disease which seriously threaten the health of human beings.Type 1 and type 2 diabetes respectively results from being destroyed and insufficient beta-cell mass.The associated symptoms appear until 50%-60%decrease of beta-cell mass.Because pancreas is deeply located in the body, with few beta-cell mass, the current methods of clinical diagnosis are invasive and late.So diagnosis of metabolism disease of beta-cell early and non-invasively becomes more and more popular, imaging diagnosis of diabetes mellitus becomes the focus of researches, but how to estimate the mass of beta-cellis still an important subject in imaging technology.-
Key words:
- Diabetes mellitus /
- Insulin-secreting cell /
- Positron-emission tomography
-
[1] Gimi B, Leoni L, Oberholzer J, etal. Functional MR microimaging of pancreatic beta-cell activation. Cell Transplant, 2006, 15(2): 195-203. doi: 10.3727/000000006783982151 [2] Zhang S, TrokowskiR, Sherry AD. A paramagnetic CEST agent for imaging glucose by MRI. J Am Chem Soc, 2003, 125(50): 15288-15289. doi: 10.1021/ja038345f [3] Sweet IR, Cook DL, Lernmark A, et al. Systematic screening of potentialbeta-cellimaging agents. Biochem Biophys Res Commun, 2004, 314(4): 976-983. doi: 10.1016/j.bbrc.2003.12.182 [4] Shiue CY, Schmitz A, Schirrmacher R, etal. Potentialapproaches for beta cellimaging with PET and SPECT. Curr Med Chem, 2004, 4(4): 271-280. [5] Schneider S, Feilen PJ, Schreckenberger M, et al. In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes, 2005, 113(7): 388-395. doi: 10.1055/s-2005-865711 [6] Olsen KM, Kearns GL, Kemp SF. Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes. J Clin Pharmacol, 1995, 35(7): 739-745. doi: 10.1002/j.1552-4604.1995.tb04115.x [7] Clark PB, Gage HD, Brown-ProctorC, etal. Neurofunctional imaging of the pancreas utilizing the cholinergic PET radioligand [18F]4-fluorobenzyltrozamicol. Eur J Nucl Med Mol Imaging, 2004, 31(2): 258-260. doi: 10.1007/s00259-003-1350-7 [8] MaffeiA, Liu Z, WitkowskiP, etal. Identification of tissue restricted transcripts in human islets. Endocrinology, 2004, 145(10): 4513-4521. doi: 10.1210/en.2004-0691 [9] Kung MP, Hou C, Lieberman BP, etal. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med, 2008, 49(7): 1171-1176. [10] Eriksson O, Jahan M, Johnström P, etal. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cellmass. Nucl Med Biol, 2010, 37(3): 357-363. doi: 10.1016/j.nucmedbio.2009.12.004 [11] Ladriěre L, Malaisse-Lagae F, Alejandro R, etal. Pancreatic fate of a(125)I-labelled mouse monoclonalantibody directed againstpancreatic B-cell surface ganglioside(s)in control and diabetic rats. Cell Biochem Funct, 2001, 19(2): 107-115. doi: 10.1002/cbf.903 [12] Eng J, Kleinman WA, Singh L, etal. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem, 1992, 267(11): 7402-7405. [13] Chen J, Yu L, Wang L, et al. Stability of synthetic exendin-4 in human plasma in vitro. Protein Pept Lett, 2007, 14(1): 19-25. [14] López de Maturana R, Willshaw A, Kuntzsch A, etal. The isolated N-terminaldomain of the glucagon-like peptide-1(GLP-1)receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem, 2003, 278(12): 10195-10200. doi: 10.1074/jbc.M212147200 [15] Körner M, Stöckli M, Waser B, etal. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med, 2007, 48(5): 736-743. [16] Gotthardt M, Lalyko G, van Eerd-Vismale J, etal. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in smallrodents. Regul Pept, 2006, 137(3): 162-167. [17] Lu Y, Dang H, Middleton B, et al. Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad SciUSA, 2006, 103(30): 11294-11299. doi: 10.1073/pnas.0603909103 [18] Lu Y, Dang H, Middleton B, et al. Long-term monitoring of transplanted islets using positron emission tomography. Mol Ther, 2006, 14(6): 851-856.
计量
- 文章访问数: 1770
- HTML全文浏览量: 516
- PDF下载量: 2